Abstract
Many risk factors are recognized for the development of endometrial cancer (EMC). A strong risk factor for hereditary nonpolyposis colonic cancer is an indication for EMC screening. Any women at risk must be counseled and evaluated in detail about their risk for many cancers, especially colonic and EMC. This is usually done in higher levels of health service rather than in a low resource setting. Also, the data concerning risk have been derived in these higher resource settings and are not necessarily transferable to other populations. For EMC, the screening methods comprise an annual transvaginal ultrasound beginning at 30–35 years of age and periodic endometrial sampling. EMC screening is not recommended in any woman with low or moderate risk or those without familial predisposition. Nevertheless, patients should be educated for the signs or symptoms suggesting an endometrial lesion, such as postmenopausal bleeding. An endometrial biopsy with a small cannula is considered an initial diagnostic step. This procedure can be performed in an out-patient setting while uterine curettage is reserved for a woman with inadequate, inconclusive, or hyperplasic tissue from endometrial biopsy. Transvaginal ultrasonography may be useful as an adjunct in selected cases depending on the availability, physician training, or resource setting. Hysteroscopy, as a diagnostic and therapeutic maneuver, requires specialized operative skill and may not be available in limited health care environments.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13:295–308.
Sorosky JI. Endometrial cancer. Obstet Gynecol. 2008;111:436–47.
Tangjitgamol S, Anderson BO, See HT, Lertbutsayanukul C, Sirisabya N, Manchana T, et al. Asian Oncology Summit. Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10:1119–27.
Anderson BO, Yip CH, Smith RA, Shyyan R, Sener SF, Eniu A, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer. 2008;113:2221–43.
Henderson BE. The cancer question: an overview of recent epidemiologic and retrospective data. Am J Obstet Gynecol. 1989;161:1859–64.
Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ. 1989;298:147–51.
Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control. 1999;10:253–60.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.
Aiman J, Forney JP, Parker Jr CR. Secretion of androgens and estrogens by normal and neoplastic ovaries in postmenopausal women. Obstet Gynecol. 1986;68:1–5.
Coulam CB, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol. 1983;61:403–7.
Silverberg SG. Hyperplasia and carcinoma of the endometrium. Semin Diagn Pathol. 1988;5:135–53.
Fenoglio CM, Crum CP, Ferenczy A. Endometrial hyperplasia and carcinoma. Are ultrastructural, biochemical and immunocytochemical studies useful in distinguishing between them? Pathol Res Pract. 1982;174:257–84.
Sherman ME, Silverberg SG. Advances in endometrial pathology. Clin Lab Med. 1995;15:517–43.
Silverberg SG. Problems in the differential diagnosis of endometrial hyperplasia and carcinoma. Mod Pathol. 2000;13:309–27.
Kendall BS, Ronnnett BM, Isacson C, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well differentiated carcinoma. Am J Surg Pathol. 1998;22:1012–9.
Trimble C, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ, et al. Concurrent endometrial carcinoma in women with biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006;106:812–9.
Committee on Gynecologic Practice, The American College of Obstetricians and Gynecologists. ACOG committee opinion. Tamoxifen and endometrial cancer. Int J Gynecol Obstet. 2006;107:1475–8.
Formander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfverswärd C, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. 1989;2:117–20.
Andersson M, Storm HH, Mouridse HT. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol. 1992;31:259–63.
Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86:527–37.
Curtis RE, Boice Jr JD, Shriner DA, et al. Second cancer after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst. 1996;88:8332–4.
Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 2004;94:256–66.
Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 1993;11:485–90.
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11:1135–41.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.
Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006;106:2376–81.
Zhang Y, Liu Z, Yu X, Zhang X, Lü S, Chen X, et al. The association between metabolic abnormality and endometrial cancer: a large case-control study in China. Gynecol Oncol. 2010;117:41–6.
Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control. 2009;16:14–22.
Ollikainen M, Abdel-Rahman WM, Moisio AL, Lindroos A, Kariola R, Järvelä I, et al. Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? J Clin Oncol. 2005;23:4609–16.
Obermair A, Youlden DR, Young JP, Lindor NM, Baron JA, Newcomb P, et al. Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. Int J Cancer. 2010;127:2678–84.
Beiner ME, Finch A, Rosen B, Lubinski J, Moller P, Ghadirian P, et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol. 2007;104:7–10.
Parazzini F, Negri E, La Vecchia C, Benzi G, Chiaffarino F, Polatti A, et al. Role of reproductive factors on the risk of endometrial cancer. Int J Cancer. 1998;76:784–6.
Prentice RL, Thomson CA, Caan B, Hubbell FA, Anderson GL, Beresford SA, et al. Low-fat dietary pattern and cancer incidence in the Women’s Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst. 2007;99:1534–43.
Unfer V, Casini ML, Costabile L, Mignosa M, Gerli S, Di Renzo GC. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2004;82:145–8. quiz 265.
Setiawan VW, Monroe KR, Goodman MT, Kolonel LN, Pike MC, Henderson BE. Alcohol consumption and endometrial cancer risk: the multiethnic cohort. Int J Cancer. 2008;122:634–8.
Bravi F, Scotti L, Bosetti C, Gallus S, Negri E, La Vecchia C, et al. Coffee drinking and endometrial cancer risk: a metaanalysis of observational studies. Am J Obstet Gynecol. 2009;200:130–5.
Tang NP, Li H, Qiu YL, Zhou GM, Ma J. Tea consumption and risk of endometrial cancer: a metaanalysis. Am J Obstet Gynecol. 2009;201:605.e1–8.
Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009;59:27–41.
Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–32.
Brown GJ, St John DJ, Macrae FA, Aittomäki K. Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: implications for gynecologic surveillance. Gynecol Oncol. 2001;80:346–9.
Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. 2006;296:1507–17.
Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338:1481–7.
Lu KH, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, et al. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol. 2007;25:5158–64.
Wright TC, Massad S, Dunton C, Spitzer M, Wilkinson EJ, Solomon D, for the 2006 American Society for Colposcopy and Cervical Pathology—sponsored Consensus Conference ASCCP. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197:346–55.
Sorosky JI. Endometrial Cancer. Obstet Gynecol. 2012;120:383–97.
Karlsson B, Granberg S, Wikland M, Ylöstalo P, Torvid K, Marsal K, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding—a Nordic multicenter study. Am J Obstet Gynecol. 1995;172:1488–94.
Goldstein S. The role of transvaginal ultrasound or endometrial biopsy in the evaluation of the menopausal endometrium. Am J Obs Gyn. 2009;201:5–11.
Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000;89:1765–72.
Lipscomb GH, Lopatine SM, Stovall TG, Ling FW. A randomized comparison of the Pipelle, Accurette, and Explora endometrial sampling devices. Am J Obstet Gynecol. 1994;170:591–4.
Larson DM, Johnson KK, Broste SK, Krawisz BR, Kresl JJ. Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol. 1995;86:38–42.
Frumovitz M, Singh DK, Meyer L, Smith DH, Wertheim I, Resnik E, et al. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol. 2004;95:463–8.
Clark TJ, Mann CH, Shah N, Khan KS, Song F, Gupta JK. Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial hyperplasia. Acta Obstet Gynecol Scand. 2001;80:784–93.
Obermair A, Geramou M, Gucer F, Denison U, Graf AH, Kapshammer E, et al. Impact of hysteroscopy on disease-free survival in clinically stage I endometrial cancer patients. Int J Gynecol Cancer. 2000;10:275–9.
Nalaboff KM, Pellerito JS, Ben-Levi E. Imaging the endometrium: disease and normal variants. Radiographics. 2001;21:1409–24.
Zalud I, Conway C, Schulman H, et al. Endometrial and myometrial thickness and uterine blood low in postmenopausal women: the influence of hormonal replacement therapy and age. J Ultrasound Med. 1993;12:737–41.
Fleischer AC. Sonographic assessment of endometrial disorders. Semin Ultrasound CT MR. 1999;20:259–66.
Sahakain V, Syrop C, Turner D. Endometrial carcinoma: transvaginal ultrasonography prediction of depth of myometrial invasion. Gynecol Oncol. 1991;43:217–9.
Savelli L, Testa AC, Mabrouk M, Zannoni L, Ludovisi M, Seracchioli R, et al. A prospective blinded comparison of the accuracy of transvaginal sonography and frozen section in the assessment of myometrial invasion in endometrial cancer. Gynecol Oncol. 2012;124(3):549–52.
Ozdemir S, Celik C, Emlik D, Kiresi D, Esen H. Assessment of myometrial invasion in endometrial cancer by transvaginal sonography, Doppler ultrasonography, magnetic resonance imaging and frozen section. Int J Gynecol Cancer. 2009;19(6):1085–90.
Dubinsky TJ. Value of sonography in the diagnosis of abnormal vaginal bleeding. J Clin Ultrasound. 2004;32:348–53.
Gull B, Carlsson SA, Karlsson B, et al. Transvaginal ultrasound in the endometrium in women with post-menopausal bleeding: is it always necessary to perform an endometrial biopsy? Am J Obstet Gynecol. 2000;182:509.
Einerth Y. Vacuum curettage by the Vabrar method: a simple procedure for endometrial diagnosis. Acta Obstet Gynecol Scand. 1982;61:373–6.
Lidor A, Ismajovich B, Confino E, David MP. Histopathological findings in 226 women with postmenopausal uterine bleeding. Acta Obstet Gynecol Scand. 1986;65:41–3.
Ferenczy A, Shore M, Guralnick M, Gelfand MM. The Kevorkian curette: an appraisal of its effectiveness in endometrial evaluation. Obstet Gynecol. 1979;54:262–7.
Stovall TG, Photopulos GJ, Poston WM, Ling FW, Sandles LG. Pipelle endometrial sampling in patients with known endometrial carcinoma. Obstet Gynecol. 1991;77:954–6.
Medverd JR, Dubinsky TJ. Cost analysis model: US versus endometrial biopsy in evaluation of peri- and postmenopausal abnormal vaginal bleeding. Radiology. 2002;222:619–27.
Gull B, Karlsson B, Milsom I, Granberg S. Can ultrasound replace dilation and curettage? A longitudinal evaluation of postmenopausal bleeding and transvaginal sonographic measurement of the endometrium as predictors of endometrial cancer. Am J Obstet Gynecol. 2003;188:401–8.
Goldstein RB, Bree RL, Benson CB, Benacerraf BR, Bloss JD, Carlos R, et al. Evaluation of the woman with postmenopausal bleeding: Society of Radiologists in Ultrasound—sponsored consensus conference statement. J Ultrasound Med. 2001;20:1025–36.
Goldstein SR. Modern evaluation of the endometrium. Obstet Gynecol. 2010;116(1):168–76.
Burbos N, Musonda P, Crocker SG, Morris EP, Nieto JJ, Duncan TJ. Management of postmenopausal women with vaginal bleeding when the endometrium cannot be visualized. Acta Obstet Gynecol Scand. 2012;91(6):686–91.
Fleischer AC, Wheeler JE, Lindsay I, et al. An assessment of the value of ultrasonographic screening for endometrial disease in postmenopausal women without symptoms. Am J Obstet Gynecol. 2001;184:70–5.
Jacobs I, Gentry-Maharaj A, Burnell M, et al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol. 2011;12:38–48.
Smith-Bindman R, Kerlikowske K, Feldstein VA. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA. 1998;280(17):1510–7.
Burbos N, Musonda P, Crocker SG, Morris EP, Nieto JJ, Duncan TJ. Outcome of investigations for postmenopausal vaginal bleeding in women under the age of 50 years. Gynecol Oncol. 2012;125(1):120–3.
Alcazar JL, Galvan R. Three-dimensional power Doppler ultrasound scanning for the prediction of endometrial cancer in women with postmenopausal bleeding and thickened endometrium. Am J Obstet Gynecol. 2009;200:44.e1–6.
Galvan R, Merce L, Jurado M, et al. Three-dimensional power Doppler angiography in endometrial cancer: correlation with tumor characteristics. Ultrasound Obstet Gynecol. 2010;35:723–9.
Liu ZZ, Jiang YX, Dai Q, Yang M, Zhu QL, Zhao DC, et al. Imaging of endometrial carcinoma using contrast-enhanced sonography. J Ultrasound Med. 2011;30(11):1519–27.
Lieng M, Qvigstad E, Dahl GF, Istre O. Flow differences between endometrial polyps and cancer: a prospective study using intravenous contrast-enhanced transvaginal color flow Doppler and three-dimensional power Doppler ultrasound. Ultrasound Obstet Gynecol. 2008;32(7):935–40.
Song Y, Yang J, Liu Z, Shen K. Preoperative evaluation of endometrial carcinoma by contrast-enhanced ultrasonography. BJOG. 2009;116(2):294–8; discussion 298–9.
Ferrazzi E, Zupi E, Leone FP, Savelli L, Omodei U, Moscarini M, et al. How often are endometrial polyps malignant in asymptomatic postmenopausal women? A multicenter study. Am J Obstet Gynecol. 2009;200:235.e1–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Tangjitgamol, S., Kavanagh, J., Shetty, M.K. (2013). Endometrial Cancer: Risk Factors and Early Diagnosis in Low-Resource Countries. In: Shetty, M. (eds) Breast and Gynecological Cancers. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1876-4_8
Download citation
DOI: https://doi.org/10.1007/978-1-4614-1876-4_8
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-1875-7
Online ISBN: 978-1-4614-1876-4
eBook Packages: MedicineMedicine (R0)